Loading Calculator...
Please wait a moment
Please wait a moment
Calculate the body surface area (BSA) affected by psoriasis to determine severity classification and guide treatment decisions.
Body surface area (BSA) assessment is crucial for determining psoriasis severity and guiding treatment decisions. The extent of skin involvement directly impacts quality of life and treatment selection.
Standard anatomical approach dividing the body into regions:
The patient's palm (including fingers) represents approximately 1% of total BSA. This is a quick estimation method where you count how many palm areas would cover the affected skin.
While BSA is important, other factors also influence treatment decisions including location of lesions (face, hands, genitals have greater impact), patient quality of life, and presence of psoriatic arthritis. High-impact areas may warrant more aggressive therapy even with lower BSA.
BSA (Body Surface Area) refers to the percentage of total skin surface affected by psoriasis lesions. It's a key metric for determining disease severity and selecting appropriate treatment options.
The palm method (including fingers) provides a quick estimation where one palm equals approximately 1% BSA. While convenient, it may be less precise than the rule of 9s for larger areas but is useful for rapid assessment.
No, 5% BSA falls in the moderate category (3-10% BSA). However, location matters - 5% BSA affecting highly visible areas like the face or hands may have greater impact on quality of life than 5% on the trunk.
Systemic therapy is typically considered for BSA >10%, BSA 3-10% with inadequate response to topical therapy, or any BSA involving high-impact areas significantly affecting quality of life. Psoriatic arthritis also influences this decision.
No, treatment decisions consider multiple factors including BSA, location of lesions, impact on quality of life, presence of psoriatic arthritis, comorbidities, and patient preferences. BSA is one important component of comprehensive assessment.
BSA should be assessed at baseline and during follow-up visits to monitor treatment response. Typical reassessment intervals are every 3-6 months, or more frequently when initiating or adjusting therapy.
A 75% reduction in BSA and severity (PASI 75) is considered a good response, while 90% reduction (PASI 90) is excellent, and complete clearance (PASI 100) is the ideal goal for many biologic therapies.
Yes, psoriasis is a chronic relapsing condition. BSA can fluctuate due to various factors including stress, infections, medications, weather changes, and treatment adherence. Regular monitoring helps track these changes.
Calculate Psoriasis Area and Severity Index score
Assess eczema severity using SCORAD index
Track urticaria activity with weekly score
Calculate body mass index and health status
Assess medication allergy cross-reactivity risk
Estimate body fat percentage using measurements